$4.46
0.45% yesterday
Nasdaq, Jun 05, 10:00 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Stock price

$4.46
+0.99 28.53% 1M
+1.42 46.71% 6M
+1.05 30.79% YTD
-0.07 1.55% 1Y
-51.44 92.02% 5Y
-51.44 92.02% 10Y
-51.44 92.02% 20Y
Nasdaq, Closing price Thu, Jun 05 2025
+0.02 0.45%
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key metrics

Market capitalization $1.00b
Enterprise Value $541.99m
P/E (TTM) P/E ratio 4.85
EV/FCF (TTM) EV/FCF 3.31
EV/Sales (TTM) EV/Sales 0.91
P/S ratio (TTM) P/S ratio 1.68
P/B ratio (TTM) P/B ratio 1.36
Revenue growth (TTM) Revenue growth 787.55%
Revenue (TTM) Revenue $598.12m
EBIT (operating result TTM) EBIT $224.16m
Free Cash Flow (TTM) Free Cash Flow $163.51m
Cash position $504.91m
EPS (TTM) EPS $0.92
P/E forward negative
P/S forward 11.77
EV/Sales forward 6.35
Short interest 4.35%
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CureVac N.V. forecast:

4x Buy
57%
2x Hold
29%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a CureVac N.V. forecast:

Buy
57%
Hold
29%
Sell
14%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
598 598
788% 788%
100%
- Direct Costs 74 74
55% 55%
12%
524 524
631% 631%
88%
- Selling and Administrative Expenses 73 73
19% 19%
12%
- Research and Development Expense 171 171
36% 36%
29%
247 247
180% 180%
41%
- Depreciation and Amortization 23 23
7% 7%
4%
EBIT (Operating Income) EBIT 224 224
167% 167%
37%
Net Profit 206 206
166% 166%
34%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Neutral
Accesswire
17 days ago
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected in Q2 2025 Glioblastoma study fully enrolled with Part B of Phase 1 CVGBM trial completing enrolment in Q1 2025; go/no-go decision on moving to Ph...
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 904
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today